Intellectual property law: A primer for scientists

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 23, Issue 3, 2003, Pages 213-224

  Brown, William M ^a  

^a Restoragen Inc   (United States)

Author keywords

Copyright; Intellectual property; Patent; Trade secret; Trademark

Indexed keywords

LAW; LEGAL ASPECT; PATENT; PUBLICATION; PUBLISHING; REVIEW; SCIENTIFIC LITERATURE;

BIOCHEMISTRY; BIOTECHNOLOGY; COMMERCE; CONFIDENTIALITY; COPYRIGHT; DISCLOSURE; GOVERNMENT AGENCIES; INTELLECTUAL PROPERTY; OWNERSHIP; PATENTS; PUBLICATIONS; UNITED STATES;

EID: 0037336469     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:23:3:213     Document Type: Review

References (185)

1. Marshall, P. (1997) Guarding the wealth of nations. Intellectual property, copyright, and international trade and relations. Wilson Quarterly 21, 64-100.
2. Coca-Cola Bottling Co. of Shreveport, Inc. v. The Coca-Cola Co., 563 F.Supp. 1122 (D.Del. 1983).
3. Coca-Cola Bottling Co. of Shreveport, Inc. v. The Coca-Cola Co., 107 F.Supp. 288 (D.Del. 1985).
4. US Patent No. 4,683,195. Process for amplifying, detecting, and/or cloning nucleic acid sequences.
5. US Patent No. 4,683,202. Process for amplifying nucleic acid sequences.
6. Hoffman, M. (1992) Roche eases PCR restrictions. Science 255, 528.
7. Dickson, D. (1993) Licenses sought from PCR users in Britain. Nature 361, 291.
8. Barinaga, M. (1995) Scientists named in PCR suit. Science 268, 1273-1274.
9. Cohen, J. (1997) May I see your license, please? PCR patent tangle slows quick assay of HIV levels. Science 276, 1488-1491.
10. Teets v. Chromalloy Gas Turbine Corp., 83 F.3d 403 (Fed.Cir. 1996).
11. Goodwin, C.D. (1996) Technology transfer at US universities: seeking public benefit from the results of basic research. Technol. Health Care 4, 323-330
12. Bertha, S.L. (1996) Academic research: policies and practice. J. Ethnopharmacol. 51, 59-73
13. Fox, J.L. (1984) Gene splicers square off in patent courts. Science 234, 584-586.
14. Blecher, M. (1988) Dominating patents: a view from the bridge. Clin. Chem. 34, 1705-1709.
15. Sugawara, S. (1991) Drug patent race heads to the bench. Washington Post, Sept. 15, p. H1.
16. Wade, N. (1980) Supreme Court hears argument on patenting life forms. Science 208, 31-32.
17. Wade, N. (1980) Court says lab-made life can be patented. Science 208, 1445.
18. Greenhouse, L. (1980) Science may patent new forms of life, justices rule, 5 to 4: dispute on bacteria; decision assists industry in bioengineering in a variety of projects. New York Times, June 16, p. A1.
19. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
20. US Patent No. 4,237,224. Process for producing biologically functional molecular chimeras.
21. Dickson, D. (1980) Stanford and UCLA [sic; UCSF] plasmid patent. Nature 288, 527-528.
22. Beardsley, T. (1984) Cohen-Boyer patent finally confirmed. Nature 311, 3.
23. US Patent No. 4,366,246. Method for microbial polypeptide expression.
24. Ezzell, C (1987) Patent Office decision puts Genentech out in front. Nature 330, 97.
25. Norman, C. (1985) Patent dispute divides AIDS researchers. Science 230, 640-642.
26. Barnes, D.M. (1987) AIDS patent dispute settled. Science 236, 17.
27. Ezzell, C. (1988) Genentech patent. Nature 335, 105.
28. Ezzell, C. (1988) Genentech gets patent protection for tissue plasminogen activator. Nature 333, 790.
29. Swinbanks, D. (1988) Problems over TPA patent for Genentech in Japan. Nature 333, 587.
30. Swinbanks, D. (1994) Single amino-acid makes a big difference in patent court. Nature 372, 123.
31. Johnston, K. (1987) TPA patent battle continues in court. Nature 327, 546.
32. Gershon, D. (1990) Genentech wins round two. Nature 344, 692.
33. Ezzell, C. (1987) Judge confirms injunction in sandwich assay patent suit. Nature 326, 532.
34. Greene, H.E., Jr. and Duft, B.J. (1990) Disputes over monoclonal antibodies. Nature 347, 117-118.
35. Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367 (Fed.Cir. 1986)
36. US Patent No. 4,873,191. Genetic transformation of zygotes.
37. McGourty, C. (1989) Microinjection patent granted. Nature 341, 681.
38. Anon (1989) DNX gains rights to fundamental patent for DNA microinjection. Biotechnology Newswatch 9, 1.
39. Egrie, J. (1990) The cloning and production of recombinant human erythropoietin. Pharmacotherapy 10, 3S-8S.
40. Gershon, D. (1990) Amgen plays for time. Nature 344, 800.
41. Gershon, D. (1990) EPO licensing talks break down. Nature 343, 500.
42. Amgen, Inc. v. Chugai Pharmaceutical Co. Ltd., 13 U.S.P.Q.2d 1737 (D.Mass. 1990).
43. Amgen, Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200 (Fed. Cir. 1991).
44. US Patent No. 4,703,008. DNA sequences encoding erythropoietin.
45. US Patent No. 4,677,195. Homogeneous erythropoietin.
46. Gershon, D. (1990) Market machinations. Nature 344, 800.
47. Rotman, D. (1991) Xoma wins patent battle. Chemical Week, Nov. 6, p. 9.
48. Shnabel, J. (1992) The magic bullet that burst the bubble; monoclonal antibodies against Gram-negative sepsis. New Scientist 135, 31-35.
49. Barnum, A. (1992) Xoma, Centocor settle biotech patent battle. San Francisco Chronicle, July 30, p. E1.
50. Anon (1991) Centocor infringes Xoma sepsis patent. Biotech. Patent News 5, 1-2.
51. Stone (1994) Search for sepsis drugs goes on despite failures. Science 264, 365-367.
52. Anderson, C. (1993) Court favors drug 'concept' over proof. Science 261, 545.
53. Kolata, G. (1987) Imminent marketing of AZT raises problems; toxicity. Science 235, 1462-1463.
54. Palca, J. (1991) Who found AZT works for AIDS? Patent dispute between the National Institutes of Health and Burroughs Wellcome. Science 251, 1554.
55. Palca, J. (1991) Monopoly patents on AZT challenged. Science 252, 1369.
56. Greenhouse, L. (1996) Justices reject challenge of patent for AIDS drug. New York Times, Jan. 17, p. A14.
57. Ackiron, E. (1991) Patents for critical pharmaceuticals; the AZT case. Am. J. Law and Med. 17, 145-155.
58. Cochrane, J.M.T. (2000) Zidovudine's patent history. Lancet 356, 1611-1612
59. Barinaga, M. (1991) Biotech nightmare: does Cetus own PCR? Science 251, 739-740.
60. Barinaga, M. (1991) And the winner: Cetus does own PCR. Science 251, 1174.
61. Schaefer, E. (1991) Cetus retains PCR patents. Nature 350, 6.
62. E.I. Du Pont de Nemours and Co. v. Cetus Corp., 19 U.S.P.Q.2d 1174 (N.D.Cal. 1990).
63. Dickman, S. (1989) Oncomouse seeks European protection. Nature 340, 85.
64. Dickman, S. (1990) Mouse patent a step closer. Nature 347, 606.
65. Dickson, D. (1989) No patent for Harvard's mouse? Science 243, 1003.
66. Abbott, A. (1993) Protestors target European animal patents. Nature 361, 103.
67. Seide, R.K. and Giaccio, A. (1995) Patenting animals. Chemistry and Industry 16, 656-658.
68. Spurgeon, D. (1998) Harvard's 'Oncomouse' fails to win Canadian patent. Nature 393, 506
69. Editorial (1992) Gene patents. Nature 359, 348.
70. Anderson, C. (1992) NIH cDNA patent rejected: backers want to amend law. Nature 359, 263.
71. Sgaramella, V. (1993) Lawyers' delight and geneticists' nightmares: at forty, the double helix shows some wrinkles. Gene 135, 299-302.
72. Zinder, N.D. (1993) Patenting cDNA 1993: efforts and happenings. Gene 135, 295-298.
73. Roberts, L. (1992) Top HHS lawyer seeks to block NIH. Science 258, 209-210.
74. Healy, B. (1992) Special report on gene patenting. New Engl. J. Med. 327, 664-668.
75. Kiley, T.D. (1992) Patents on random complementary DNA fragments. Science 257, 915-918.
76. Adler, R.G. (1992) Genome research: fulfilling the public's expectations for knowledge and commercialization. Science 257, 908-914.
77. Eisenberg, R.S. (1992) Genes, patents, and product development. Science 257, 903-908.
78. Looney, B. (1994) Should genes be patented? The gene patenting controversy: legal, ethical, and policy foundations of an international agreement. Law and Policy in Int'l. Bus. 26, 231-272.
79. Lech, K.F. (1993) Human genes without functions: biotechnology tests the patent utility standard, Suffolk Univ. Law Review 27, 1631-1660.
80. Eisenberg, R.S. and Merges, R.P. (1995) Opinion letter as to the patentability of certain inventions associated with the identification of partial cDNA sequences. AIPLA Q. J. 23, 1-52.
81. Riley, P.J. (1994) Patenting Dr. Venter's genetic findings: Is the National Institutes of Health creating hurdles or clearing the path for biotechnology's voyage into the twenty-first century? J. Contemp. Health Law and Policy 10, 309-326.
82. Aldhous, P. (1993) PCR enzyme patent challenged. Science 260, 486.
83. Abbott, A. (1996) Roche faces charges over Taq patent claim. Nature 382, 660.
84. Dickson, D. (1994) Promega files court challenge to Roche's Taq enzyme patent. Nature 372, 714.
85. White, T.J. (2000) Why Roche deserves the disputed Taq patent. Nature 403, 825-826
86. Dalton, R. (1999) Roche's Taq patent 'obtained by deceit,' rules US court. Nature 402, 709
87. Dalton, R. (2001) Patent ruling could cut PCR enzyme prices. Nature 411, 622
88. Service, R.F. (1999) Taq polymerase patent ruled invalid. Science 286, 2251-53
89. Slind-Flor, V. (1995) Chiron challenged on hepatitis-C patent. Science 267, 23.
90. Genentech, Inc. v. Chiron Corp., 112 F.3d 495 (Fed. Cir. 1997).
91. Anon (1997) Patent law. BioPharm, May 1997, p. 12.
92. Novo Nordisk of North America, Inc. v. Genentech, Inc., 77 F.3d 1364 (Fed.Cir. 1996).
93. Genentech, Inc. v. Novo Nordisk, A/S, 108 F.3d 1361 (Fed.Cir. 1997).
94. Dalton, R. (1999) US jury split over hormone patent case... Nature 399, 512
95. Dalton, R. (1999) Charges fly in $1bn hormone patent battle. Nature 399, 289
96. Barinaga M. (1999) No winners in patent shootout. Science 284, 1752-53
97. Marx, J. (1996) A second breast cancer susceptibility gene found; BRCA2. Science 271, 30.
98. Marshall, E. (1997) The battle of BRCA1 goes to court; BRCA2 may be next. Science 278, 1874.
99. Butler, D. and Goodman, S. (2001) French researchers take a stand against cancer gene patent. Nature 413, 95-96
100. Wadman, M. (2000) US court tests the breadth of patent protection on proteins. Nature 404, 532
101. Kauffman, S.A. (1999) Patent amplification. Nature Biotech. 17, 408 [letter to the editor]
102. Campell, C. (1999) Patent amplification. Nature Biotech. 17, 408 [letter to the editor]
103. Dove, A. (2000) Opinions evolve on Kauffman patent. Nature Biotech. 18, 373
104. US Patent No. 5,723,323. Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof.
105. Baleta A. (2001) Drug firms lose patent rights lawsuit against South Africa's government. Lancet 357, 1347
106. Dalton, R. (2000) Patent suit on Alzheimer's mouse rejected... Nature 405, 989
107. Dickson, D. (2000) Affymetrix loses first round of patent battle. Nature 404, 697.
108. Fox, J.L. (2001) Canadian farmer found guilty of Monsanto canola patent infringement. Nature Biotech. 18, 396-397
109. Melzer, D. (1998) Patent protection for medical technologies; why some and not others? Lancet 351, 518-519
110. Brewer, C. (1998) Patent protection for medical technologies. Lancet 351, 1591-1592
111. Shulman, S. (1999) Staking a claim on medical knowledge. The patent profusion. Minn. Med. 82, 12-19
112. Antonuk, L.E., Sprawls, P., and Hendee, W.R. (1999) Medical physicists should seek patent protection for new ideas before publishing articles about them. Med. Phys. 26, 2220-2222
113. Marshall, E. (2000) Biotech giants butt heads over cancer drug. Science 288, 2303
114. Malakoff, D. (2000) Patent prompts Rochester to sue for slice of drug profits. Science 288, 410-411
115. Anon (2001) Patent protection versus public health. Lancet 358, 1563
116. Malakoff, D. (2001) Will a smaller genome complicate the patent chase? Science 291, 1194
117. Saegusa A. (1999) Japan joins efforts to patent cDNA clones. Nature 401, 520
118. Robertson, D. (1999) EST patent granted for human kinase homologs. Nature Biotech. 17, 125
119. Reichhardt, T. (1998) Patent on gene fragment sends researchers a mixed message... Nature 396, 499
120. Gold, E.R. (2000) Moving the gene patent debate forward. Nature Biotech. 18, 1319-1320
121. Sherrid, P. (2001) It's all about cures and cash. US News World Report, Jan. 8, 35-36
122. Forman D.S. and Diner, B.C. (2001) Emerging new biotechnologies and the patent attorneys' struggle to best protect them. Trends Biotech. 19, 4-5
123. Reynolds, T. (2000) Pricing human genes: the patent rush pushes on. J. Nat'l Cancer Inst. 92, 96-97
124. Reynolds, T. (2000) Gene patent race speeds ahead amid controversy, concern. J. Nat'l Cancer Inst. 92, 184-186
125. Senior, K. (2000) Patent and be damned: the new slogan for human genetics? Mol. Med. Today 6, 255-256
126. Caulfield, T.A. and Gold, E.R. (2000) Genetic testing, ethical concerns, and the role of patent law. Clin. Genet. 57, 370-375
127. Anon (1999) The scramble to patent human genes. Nat. Neurosci. 2, 773
128. Schonmann, A. (1998) From make believe to doomsday eve: or should we patent genes? Med. Law 17, 455-476
129. Praiss, D.M. (2001) Creating a winning patent portfolio. Nature Biotech. 19 (suppl.), BE5-BE7
130. Gogoris, A.C. and Clarke, P.J. (2001) Patent due diligence in biotechnology transactions. Nature Biotech. 19, 279-281
131. DiMasi, J.A., Hansen, R.W., Grabowski, H.G., and Lasagna, L. (1995) Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. Pharmacoeconomics 7, 152-169
132. Köhler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibodies of predefined specificity. Nature 256, 495-497.
133. Uhr, J.W. (1984) The 1984 Nobel Prize in medicine. Science 226, 1025-1028.
134. Köhler, G. (1984) Derivation and diversification of monoclonal antibodies. Scand. J. Immunol. 37, 117-129.
135. Cohen, S.N., Chang, A.C.Y., Boyer, H.W., and Helling, R.B. (1993) Construction of biologically functional bacterial plasmids in vitro. Proc. Natl. Acad. Sci. USA 70, 3240-3244.
136. Lehrman, S. (1993) Stanford seeks life after Cohen-Boyer patent expires. Nature 363, 574.
137. Anon (1990) Stanford updates bottom lines on Cohen-Boyer patent users. Biotech. Newswatch 10, 8.
138. US Patent No. 4,571,421. Mammalian gene for microbial expression.
139. Falcoila, L. (2000) Rewarding true innovation. Experimental use exemption and the trends in gene patenting. EMBO Reports 1, 200-203
140. Barton, J.H. (2000) Reforming the patent system. Science 287, 1933-1934
141. US Patent No. 3,461,461. 6-Amino-4-(subsituted amino)-1,2,-dihydro-1-hydroxy-2-iminopyrimidines.
142. Greminger, P., Foerster, E., Vetter, H., Baumgart, P., Vetter, W. (1986) Minoxidil and captopril in severe hypertension. Klin. Wochenschr. 64, 327-332
143. Oh, M.S., Uribarri, J., Alveranga, D., Bazilinski, N., Lazar, I., Carroll, H.J. (1985) Minoxidil in a once-a-day step-3 antihypertensive program. J. Clin. Hypertens. 1, 23-29
144. Pettinger, W.A. (1980) Minoxidil and the treatment of severe hypertension. N. Engl. J. Med. 303, 922-926
145. Kosman, M.E. (1980) Evaluation of a new antihypertensive agent. Minoxidil. JAMA 244, 73-75
146. US Patent No. 4,139,619. 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth.
147. US Patent No. 4,596,812. Methods and solutions for treating male pattern alopecia.
148. Katz, H.I. (1989) Topical minoxidil: review of efficacy and safety. Cutis 43, 94-98
149. Kowalski, T.J. (2000) Analyzing the USPTO's revised utility guidelines. Nature Biotech. 18, 349-350
150. Kowalski, T.J. (2000) Analyzing the new written description guidelines. Nature Biotech. 18, 461-462
151. Enserink, M. (2000) Patent office may raise the bar on gene claims. Science 287, 1196-1197
152. Blumenthal, D., Campbell, E.G., Anderson, M.S., Causino, N., and Louis, K.S. (1997) Withholding research results in academic life science. Evidence from a national survey of faculty. JAMA 277, 1224-1228.
153. Windman, M. (1996) Commercial interests delay publication. Nature 379, 574.
154. US Patent No. 4,736,866. Transgenic non-human mammals.
155. Anderson, A. (1987) Animal patent dispute out in the open at congressional hearings. Nature 327, 546.
156. Booth, W. (1988) Animals of invention. Science 240, 718.
157. Hooper, C. (1987) Patenting brave new animals: religion, economics, biotech meet in Capitol Hill battle. United Press Int'l. Newswire, Aug. 15, 1987.
158. Stone, R. (1995) Religious leaders oppose patenting genes and animals. Science 268, 1126.
159. Stewart, T.A., Pattengale, P.K., and Leder, P. (1984) Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38, 627-637.
160. Leder, A., Pattengale, P.K., Kuo, A., Stewart, T.A., and Leder, P. (1986) Consequences of widespread deregulation of the c-myc gene in transgenic mice; multiple neoplasms and normal development. Cell 45, 485-495.
161. Lehrman, S. (1993) Ruling narrows US view of animal patents. Nature 361, 103.
162. Bizley, R.E. (1991) Patenting animals in Europe. Biotech. 9, 619-622.
163. Editorial (1996) One way out of a patent quagmire. Nature 381, 175.
164. Porter, J.R. (2000) Patent confusion in law on new plant varieties. Nature 404, 13 [letter to the editor]
165. Abbott, A. (1998) Europe's life patent moratorium may go... Nature 393, 200
166. Spillmann-Fürst, I. (1999) Europe edges closer to GMO patent harmonization. Nature Biotech. 17, 842-843.
167. Bunnin, B. (1985) Protecting intellectual property: copyright for journal authors and conference speakers. Birth 12 (suppl. 3) 29-31.
168. Liedes, J. (1997) Copyright: evolution, not revolution. Science 276, 223-225.
169. Dobkin, D.S. (1979) Copyright law undergoes major face-lift. JAMA 241, 1019-1020.
170. Henry, N.L. (1974) Copyright: its adequacy in technological societies. Science 186, 993-1004.
171. Frisse, M.E. and Tolva, J.N. (1996) The commerce of ideas: copyright in the digital era. Acad. Med. 71, 45-53.
172. Vardy, J. (1997) Copyright move on photocopies will cost banks and lawyers dear. Financial Post, May 20, p. 1.
173. American Geophysical Union v. Texaco, Inc., 60 F.3d 913 (2d Cir. 1995).
174. National Conference of Lawyers and Scientists (1995) How does the Texaco case affect photocopying by scientists? Science 270, 1450-1451.
175. Lawler, A. (1995) Texaco offers to settle copyright case. Science 268, 1127.
176. Helminski, F. (1993) Use and abuse of medical service marks. Mayo Clin. Proc. 68, 1212-1213.
177. Mayo Clinic v. Mayo's Drug and Cosmetic, Inc., 113 N.W.2d 852 (Minn. 1962).
178. Editorial (1995) Names for hi-jacking. Nature 373, 370.
179. Chesnoff, S. (1995) The use of Taxol as a trademark. Nature 374, 208 [letter to the editor].
180. Khan, N.U. (1995) Taxol trademark. Nature 374, 400 [letter to the editor].
181. Wani, M.C., Taylor, H.L., Wall, M.E., Coggon, P. and McPhail, A.T. (1971) Plant anti-tumor agents. VI. The isolation and structure of Taxol. A novel anti-leukemic and anti-tumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325-2327.
182. Nicolaou, K.C., Liu J.J., Ueno, H., Nantermet, P.G., Guy, R.K., Claiborne, C.F., Renaud, J., Couladouros, E.A., Paulvannan, K., and Sorensen, E.J. (1994) Total synthesis of Taxol. Nature 367, 630-634.
183. Jack, D.B. (1997) One hundred years of aspirin. Lancet 350, 437-439.
184. Bayer Co., Inc. v. United Drug Co., 272 F. 505 (S.D.N.Y. 1921).
185. Wood, A. (1997) New recognition for an old name. Chemical Week, Sept. 10, 1997, p. 51.